PE20200337A1 - Receptores de celulas t novedosos, e inmunoterapia usando los mismos - Google Patents

Receptores de celulas t novedosos, e inmunoterapia usando los mismos

Info

Publication number
PE20200337A1
PE20200337A1 PE2019002620A PE2019002620A PE20200337A1 PE 20200337 A1 PE20200337 A1 PE 20200337A1 PE 2019002620 A PE2019002620 A PE 2019002620A PE 2019002620 A PE2019002620 A PE 2019002620A PE 20200337 A1 PE20200337 A1 PE 20200337A1
Authority
PE
Peru
Prior art keywords
antigen
spink2
recognizing constructs
taa
tcr
Prior art date
Application number
PE2019002620A
Other languages
English (en)
Inventor
Claudia Wagner
Dominik Maurer
Sebastian Bunk
Leonie Alten
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of PE20200337A1 publication Critical patent/PE20200337A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8135—Kazal type inhibitors, e.g. pancreatic secretory inhibitor, ovomucoid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invencion se refiere a constructos reconocedores de antigeno dirigidos contra antigenos asociados a tumores (TAA), en particular contra el TAA denominado inhibidor de serina peptidasa Kazal de tipo 2 (SPINK2). La invencion proporciona, en concreto, moleculas novedosas basadas en un nuevo receptor de celulas T (TCR) que son selectivas y especificas hacia el antigeno de la invencion que es expresado por tumores. El TCR de la invencion, asi como los fragmentos de union con el antigeno SPINK2 y que derivan del mismo, estan destinados al uso en el diagnostico, el tratamiento y la prevencion de enfermedades tumorales que expresan el SPINK2. Ademas, se proporcionan acidos nucleicos que codifican los constructos reconocedores del antigeno de la invencion, los vectores que comprenden esos acidos nucleicos, las celulas recombinantes que expresan los constructos reconocedores del antigeno, y las composiciones farmaceuticas que comprenden los compuestos de la invencion.
PE2019002620A 2017-06-30 2018-06-28 Receptores de celulas t novedosos, e inmunoterapia usando los mismos PE20200337A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762527844P 2017-06-30 2017-06-30
DE102017114737.3A DE102017114737A1 (de) 2017-06-30 2017-06-30 Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
PCT/EP2018/067380 WO2019002444A1 (en) 2017-06-30 2018-06-28 NEW T CELL RECEPTORS AND IMMUNOTHERAPY USING THE SAME

Publications (1)

Publication Number Publication Date
PE20200337A1 true PE20200337A1 (es) 2020-02-14

Family

ID=64662173

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019002620A PE20200337A1 (es) 2017-06-30 2018-06-28 Receptores de celulas t novedosos, e inmunoterapia usando los mismos

Country Status (20)

Country Link
US (4) US10590194B2 (es)
EP (1) EP3645573A1 (es)
JP (1) JP7235316B2 (es)
KR (1) KR20200023288A (es)
CN (1) CN110753705A (es)
AR (1) AR112604A1 (es)
AU (1) AU2018293322A1 (es)
BR (1) BR112019025323A2 (es)
CA (1) CA3067757A1 (es)
CL (1) CL2019003885A1 (es)
CO (1) CO2020000357A2 (es)
CR (1) CR20190594A (es)
DE (1) DE102017114737A1 (es)
IL (1) IL271751A (es)
MA (1) MA49503A (es)
MX (1) MX2019015742A (es)
PE (1) PE20200337A1 (es)
SG (1) SG11201911437VA (es)
TW (1) TWI727182B (es)
WO (1) WO2019002444A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20230343A1 (es) * 2015-12-11 2023-03-01 Immatics Biotechnologies Gmbh Peptidos que estimulan respuestas inmunitarias antitumorales
US20200297768A1 (en) 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
DE102019108125B4 (de) 2019-03-28 2022-02-03 Immatics US, Inc. Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung
US11975025B2 (en) 2019-05-27 2024-05-07 Immatics US, Inc. Viral vectors and use thereof in adoptive cellular therapy
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
CN112442119B (zh) * 2019-09-05 2023-02-24 香雪生命科学技术（广东）有限公司 一种识别ssx2的高亲和力t细胞受体
KR20230012465A (ko) 2020-02-24 2023-01-26 이매틱스 유에스 인코포레이티드 암 및 관련 악성 종양을 치료하기 위해 t 세포를 확장하는 방법
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
WO2022040631A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
DE102021100038A1 (de) 2020-12-31 2022-06-30 Immatics US, Inc. Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung
JP2024502034A (ja) 2020-12-31 2024-01-17 イマティクス ユーエス，アイエヌシー． Ｃｄ８ポリペプチド、組成物、及びそれらの使用方法
CA3217739A1 (en) 2021-05-05 2022-11-10 Sebastian Bunk Bma031 antigen binding polypeptides
TW202332765A (zh) 2021-09-20 2023-08-16 美商英麥提克斯股份有限公司 用於ｔ細胞療法之ｔ細胞群體的單核球耗盡
WO2023081461A1 (en) 2021-11-08 2023-05-11 Immatics US, Inc. Methods for generating cell spheroids
WO2023212697A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2023212691A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. DOMINANT NEGATIVE TGFβ RECEPTOR POLYPEPTIDES, CD8 POLYPEPTIDES, CELLS, COMPOSITIONS, AND METHODS OF USING THEREOF
WO2023212655A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
US20230355678A1 (en) 2022-05-05 2023-11-09 Immatics US, Inc. Methods for improving t cell efficacy

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
WO2000006732A2 (en) * 1998-07-31 2000-02-10 Diagnostic Products Corporation Polynucleotide encoding an autoantigen associated with endometriosis
CA2398136A1 (en) 2000-02-08 2001-08-16 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
GB0525999D0 (en) * 2005-12-21 2006-02-01 Ares Trading Sa Novel members of the kazal family of serine protease inhibitors
JP5808079B2 (ja) * 2007-03-05 2015-11-10 株式会社癌免疫研究所 癌抗原特異的ｔ細胞のレセプター遺伝子およびそれによりコードされるペプチドならびにそれらの使用
AU2013300549B2 (en) 2012-08-08 2019-04-11 Daiichi Sankyo Company,Limited Peptide library and use thereof
ES2745472T3 (es) * 2013-07-15 2020-03-02 The U S A As Represented By The Secretary Department Of Health And Human Services Office Of Tech Tra Receptores de células T anti-virus del papiloma humano 16 E6
GB201314404D0 (en) * 2013-08-12 2013-09-25 Immunocore Ltd T Cell Receptors
BR112017009262A2 (pt) * 2014-11-05 2018-03-06 Genentech, Inc. métodos de produção de proteínas de duas cadeias em bactérias
EP3156067A1 (en) * 2015-10-16 2017-04-19 Max-Delbrück-Centrum Für Molekulare Medizin High avidity hpv t-cell receptors
GB201520597D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520567D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201521894D0 (en) 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers

Also Published As

Publication number Publication date
BR112019025323A2 (pt) 2020-06-23
WO2019002444A1 (en) 2019-01-03
AR112604A1 (es) 2019-11-20
CA3067757A1 (en) 2019-01-03
MX2019015742A (es) 2020-02-20
AU2018293322A1 (en) 2020-01-16
WO2019002444A9 (en) 2019-03-14
US10590194B2 (en) 2020-03-17
JP2020529830A (ja) 2020-10-15
EP3645573A1 (en) 2020-05-06
SG11201911437VA (en) 2020-01-30
KR20200023288A (ko) 2020-03-04
DE102017114737A1 (de) 2019-01-03
CR20190594A (es) 2020-03-02
MA49503A (fr) 2020-05-06
US11111294B2 (en) 2021-09-07
CN110753705A (zh) 2020-02-04
JP7235316B2 (ja) 2023-03-08
IL271751A (en) 2020-02-27
US20190256590A1 (en) 2019-08-22
TW201904989A (zh) 2019-02-01
TWI727182B (zh) 2021-05-11
US20210388079A1 (en) 2021-12-16
CO2020000357A2 (es) 2020-01-31
US20200140540A1 (en) 2020-05-07
US10723796B2 (en) 2020-07-28
CL2019003885A1 (es) 2020-05-29
US20190002556A1 (en) 2019-01-03

Similar Documents

Publication Publication Date Title
PE20200337A1 (es) Receptores de celulas t novedosos, e inmunoterapia usando los mismos
PE20191493A1 (es) Receptores de linfocitos t e inmuno terapias basadas en el uso de los mismos contra canceres positivos para prame
CR20190095A (es) Nuevos receptores de linfocitos t e inmonoterapia basada en el uso de los mismos
PE20200152A1 (es) Receptores de union a antigeno mejorados
MX2020004741A (es) Nuevos receptores de las celulas t modificados geneticamente y terapias immunologicas que emplean los mismos.
CR20190278A (es) Nuevos receptores de células t y terapia inmunológica que los utiliza
MX2022015821A (es) Nuevos receptores de celulas t y usos de los mismos.
WO2018172533A3 (en) T cell receptors and immune therapy using the same against prame positive cancers
CR20190276A (es) Nuevos receptores de células t y terapia inmunológica que los utiliza
PE20171790A1 (es) Anticuerpos anti-ceacam6 y sus usos
GT201000148A (es) Anticuerpos antimesotelina y usos de los mismos
PH12019500312A1 (en) T cell receptors and immune therapy using the same
AR093788A1 (es) Inmunoterapia con agentes de enlace
PE20191703A1 (es) Formatos mejorados de receptor de union a antigeno
MX2012003058A (es) Vacunas dirigidas a celulas de langerhans.
AR067666A1 (es) Proteinas de union al antigeno del receptor de il-18
CO2019002229A2 (es) Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos
EA201992583A1 (ru) Новые t-клеточные рецепторы и иммунотерапия с их применением
AR113834A1 (es) Receptores de células t modificados genéticamente y terapias inmunológicas que emplean los mismos
AR109345A1 (es) Receptores de linfocitos t e inmunoterapia basada en el uso de los mismos
EA201992002A1 (ru) Т-клеточные рецепторы и иммунная терапия prame-положительных раковых заболеваний с их применением
AR119964A2 (es) Anticuerpos anti-cd123 y conjugados y derivados de estos
EA201990488A1 (ru) Новые t-клеточные рецепторы и иммунотерапия с их применением
AR110682A1 (es) Receptores de células t y terapia inmunológica que los utiliza
CO2019006926A2 (es) Nuevos receptores de células t y terapia inmunológica que los utiliza